Effective gene therapy with nonintegrating lentiviral vectors.

Journal article

Retroviral and lentiviral vector integration into host-cell chromosomes carries with it a finite chance of causing insertional mutagenesis. This risk has been highlighted by the induction of malignancy in mouse models, and development of lymphoproliferative disease in three individuals with severe combined immunodeficiency-X1 (refs. 2,3). Therefore, a key challenge for clinical therapies based on retroviral vectors is to achieve stable transgene expression while minimizing insertional mutagenesis. Recent in vitro studies have shown that integration-deficient lentiviral vectors can mediate stable transduction. With similar vectors, we now show efficient and sustained transgene expression in vivo in rodent ocular and brain tissues. We also show substantial rescue of clinically relevant rodent models of retinal degeneration. Therefore, the high efficiency of gene transfer and expression mediated by lentiviruses can be harnessed in vivo without a requirement for vector integration. For therapeutic application to postmitotic tissues, this system substantially reduces the risk of insertional mutagenesis.

Authors: Yáñez-Muñoz, R; Balaggan, K; MacNeil, A; Howe, S; Schmidt, M

• Publication status: Published
• Journal: Nature medicine
• Volume: 12
• Issue: 3
• Pages: 348-353
• Publication date: 2006-03-01
• DOI: 10.1038/nm1365
• EISSN: 1546-170X
• ISSN: 1078-8956
• Language: English
• Keywords: Tumor Cells, Cultured; Hela Cells; Green Fluorescent Proteins; Virus Integration; Rats; Humans; Carrier Proteins; Mice; cis-trans-Isomerases; Lentivirus; Pigment Epithelium of Eye; Brain; Electroretinography; Female; Eye Proteins; Genetic Therapy; Retina; Animals; Genetic Vectors